Others clinical variables such as breast cancer subtype (luminal vs. TNBC vs. HER2), age at diagnosis and type of therapy received (hormonotherapy vs. chemotherapy vs. cyclin-dependent kinase 4/6 inhibitor vs. anti-her2 monoclonal antibodies) were also analyzed but they were not associated with an increased risk of having lower or higher levels of the different immune markers studied. The gene discussed is ERBB2; the disease is breast carcinoma.